Raymond James Rates MapLight Therapeutics (MPLT) buy
Raymond James maintains a positive outlook on MapLight Therapeutics with a $46 price target, a 38.22% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Raymond James rated MapLight Therapeutics, Inc. ($MPLT) "buy" with a $46 price target on June 25, 2026.
Since the rating, $MPLT is up 16.1% after 1 week, down 69.0% after 1 month and down 75.9% to date (from the $31.96 close on Jun 25, 2026).
MPLT
MapLight Therapeutics, Inc.
Key Points
- Raymond James reiterated its Buy rating on MapLight Therapeutics, Inc. (MPLT) with a $46 price target on June 25, 2026.
- Raymond James's $46 price target implies 38.22% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $33.28 share price.
- Shares of MPLT traded near $30.05 on Thursday, with a market cap of approximately $1.35 billion and a 52-week range of $12.24 to $33.28.
- Peer funds like BlackRock increased their positions in MPLT, signaling interest among institutional investors.
Get $MPLT trade alerts by text
We text you when insiders, Congress or big funds trade $MPLT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MapLight Therapeutics, Inc. alert may contain errors. Disclosures
Raymond James reiterated its Buy rating for MapLight Therapeutics, Inc. (NasdaqGS: MPLT) on June 25, 2026, setting a price target of $46. The analyst behind this decision, Tiago Fauth, continues to show confidence in the biotech company's potential.
Raymond James vs. the S&P 500
Hypothetical returns from Raymond James's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in MapLight Therapeutics
Several institutional investors have shown interest in MapLight Therapeutics. BlackRock, Inc. increased its stake by 244,217 shares, ending with 1,339,731 shares valued at about $27.2 million—a 22.3% increase. Blue Owl Capital Holdings LP also significantly boosted its position, adding 678,871 shares for a total of 1,005,929 shares worth approximately $20.5 million, marking a 207.6% increase. Meanwhile, Goldman Sachs Group Inc. increased its holdings by 57,705 shares, resulting in 1,994,873 shares valued at $40.6 million, a 3.0% increase.
MapLight Therapeutics, Inc. Stock Up 315.0%
Shares of MapLight Therapeutics (NasdaqGS: MPLT) traded around $30.05 on Thursday. The company has a market capitalization of about $1.35 billion. Although it isn't currently profitable, with a forward P/E ratio of -7, the stock's 52-week range is between $12.24 and $33.28. The 50-day moving average stands at $28.92, while the 200-day moving average is $21.11. The company maintains a strong financial position with a current ratio of 22.91 and a quick ratio of 21.71, alongside a debt-to-equity ratio of 1.40.
$MPLT price target
MapLight Therapeutics, Inc. daily closes and this analyst's $46 target. Not advice.
Analysts Set New Price Targets
On June 25, 2026, Raymond James reiterated its Buy rating for MapLight Therapeutics with a $46 price target. Other firms have also shown optimism: Craig-Hallum maintained a Buy rating with a $40 target on June 23, while Needham did the same with a $42 target on June 22. The consensus among analysts is positive, with a mean price target of $38.70 based on 10 opinions.
About MapLight Therapeutics
MapLight Therapeutics, Inc. is a biotechnology company focused on developing treatments for central nervous system disorders. Based in Redwood City, California, the company is led by CEO Dr. Christopher A. Kroeger. It is working on various products, including therapies for schizophrenia, Alzheimer's disease, and autism spectrum disorders. MapLight was incorporated in 2018 and employs about 133 people, aiming to address unmet medical needs through innovative research.
Bottom Line
Raymond James' reiteration of its Buy rating for MapLight Therapeutics, along with a $46 price target, reflects continued confidence in its potential. Institutional interest, as shown by increased holdings from major funds, underscores the attention MPLT is receiving from investors. As a clinical-stage biotech firm, MapLight's progress in developing treatments for complex disorders makes it a company to watch in the healthcare sector.
Related Filing Alerts
Source: Raymond James's rating change on $MPLT (Jun 25, 2026). Written by software, not financial advice. How we make alerts